News

04/30/2024

In this Issue, we bring you excerpts from an interview with Dr. AIi Amid, co-author of ‘Guidelines for the Management of Alpha-Thalassaemia’, recently published by the Thalassaemia International Federation (TIF).

12/20/2023

In this Issue, we highlight The International Hemoglobinopathy Research Network (INHERENT)* which was established in 2020 to examine the role of genetic modifiers in hemoglobinopathies.

09/05/2023

Find out more about the 2023 Thalassaemia International Federation (TIF) Guidelines for the Management of Non-transfusion Dependent β-thalassaemia (β-NTDT) as well as new thalassemia community resources and a clinical trials update.

03/23/2023

Check out our latest issue, including an interview with thalassemia specialist Dr. Vip Viprakasit, an in-depth analysis of recent alpha-thalassemia publications, and more.

11/01/2022

In this issue, we bring you excerpts from an interview with β-thalassemia patient NinaMaria, insights on the global epidemiology of thalassemia, and more.

09/07/2022

Researching Early Indicators of Heart and Lung Damage to Improve Outcomes for Children and Young Adults with Sickle Cell Disease

07/12/2022

Rare disease biotech Agios recruits Brian Goff from Alexion as new CEO

07/12/2022

Former Alexion executive to take helm at Agios Pharmaceuticals

07/01/2022

Read our first issue of ThalassemiaNEWS, a quarterly newsletter keeping the medical and patient community in touch with thalassemia developments.

02/18/2022

After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new ‘anchor product’

02/17/2022

Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder

02/17/2022

Agios wins FDA approval for pill to treat rare blood disease

01/26/2022

Behind the Scenes with Agios Chief Medical Officer, Dr. Sarah Gheuens, on Just Listen: Voices of PK Deficiency Podcast

11/23/2021

Dr. Sarah Gheuens, Agios Chief Medical Officer, on Cheat Codes: A Sickle Cell Podcast

11/01/2021

When it comes to employee mental health, these companies put in the work

10/26/2021

Our Approach to Partnering with Patients on CheatCodes: A Sickle Cell Podcast

08/02/2021

Jackie Fouse: What The Sale Of Agios’ Oncology Pipeline Taught Me

02/12/2021

100 Most Sustainable Companies

01/21/2021

More Positive Data Sets Up Agios’ Mitapivat for Regulatory Filings This Year

12/21/2020

Agios to Sell Cancer Portfolio to Servier for $1.8 Billion

12/21/2020

Changing identity, Agios to sell cancer drug business to Servier

12/21/2020

Cambridge biotech Agios will sell oncology business to Boston’s Servier for up to $2 billion

12/21/2020

Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

12/01/2020

Agios’ anemia drug hits goal in phase 3, teeing up 2021 filing

09/16/2020

Agios CEO Jackie Fouse on FDA Orphan Drug Designated Mitapivat

07/20/2020

Why Go To The Office? Few Want To — Some Need To

06/12/2020

Cancer drugmaker Agios offers promising data from two studies testing blood disorder drug

06/12/2020

In this Issue, we bring you excerpts from an interview with Dr. AIi Amid, co-author of ‘Guidelines for the Management of Alpha-Thalassaemia’, recently published by the Thalassaemia International Federation (TIF).

In this Issue, we highlight The International Hemoglobinopathy Research Network (INHERENT)* which was established in 2020 to examine the role of genetic modifiers in hemoglobinopathies.

Find out more about the 2023 Thalassaemia International Federation (TIF) Guidelines for the Management of Non-transfusion Dependent β-thalassaemia (β-NTDT) as well as new thalassemia community resources and a clinical trials update.

Check out our latest issue, including an interview with thalassemia specialist Dr. Vip Viprakasit, an in-depth analysis of recent alpha-thalassemia publications, and more.

In this issue, we bring you excerpts from an interview with β-thalassemia patient NinaMaria, insights on the global epidemiology of thalassemia, and more.

Researching Early Indicators of Heart and Lung Damage to Improve Outcomes for Children and Young Adults with Sickle Cell Disease

Rare disease biotech Agios recruits Brian Goff from Alexion as new CEO

Former Alexion executive to take helm at Agios Pharmaceuticals

Read our first issue of ThalassemiaNEWS, a quarterly newsletter keeping the medical and patient community in touch with thalassemia developments.

After selling off Tibsovo and entire cancer pipeline, Agios nets first approval for new ‘anchor product’

Agios’ first-in-class PK activator Pyrukynd scores FDA approval to treat rare blood disorder

Agios wins FDA approval for pill to treat rare blood disease

Behind the Scenes with Agios Chief Medical Officer, Dr. Sarah Gheuens, on Just Listen: Voices of PK Deficiency Podcast

Dr. Sarah Gheuens, Agios Chief Medical Officer, on Cheat Codes: A Sickle Cell Podcast

When it comes to employee mental health, these companies put in the work

Our Approach to Partnering with Patients on CheatCodes: A Sickle Cell Podcast

Jackie Fouse: What The Sale Of Agios’ Oncology Pipeline Taught Me

100 Most Sustainable Companies

More Positive Data Sets Up Agios’ Mitapivat for Regulatory Filings This Year

Agios to Sell Cancer Portfolio to Servier for $1.8 Billion

Changing identity, Agios to sell cancer drug business to Servier

Cambridge biotech Agios will sell oncology business to Boston’s Servier for up to $2 billion

Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

Agios’ anemia drug hits goal in phase 3, teeing up 2021 filing

Agios CEO Jackie Fouse on FDA Orphan Drug Designated Mitapivat

Why Go To The Office? Few Want To — Some Need To

Cancer drugmaker Agios offers promising data from two studies testing blood disorder drug

Agios drug demonstrates strong response in patients with inherited blood disorder

Agios CEO Jackie Fouse weighs in on the healthcare space

Jackie Fouse, Admired By Investors, To Become CEO Of Biotech Agios